The use of GnRH agonists in the long protocol is characterized by some disadvantages for the patients: a) the drawback of a long treatment period until desensitization occurs [7]; b) the increased risk of the ovarian hyperstimulation syndrome (OHSS) [8]; c) more frequent occurrence of side effects (e.g., hot flushes, headache, bleeding, and cyst development) during the desensitization period [9,10]. The gene discussed is GNRH1; the disease is cyst.